Doctors Note Logo

Published on: 8/18/2026

What Is X-Linked Hypophosphatemia?

X-linked hypophosphatemia (XLH) is a rare, lifelong genetic bone disorder in which mutations in the PHEX gene drive excess FGF23, causing the kidneys to lose phosphate and leaving bones soft, weak, and poorly mineralized. Typical signs include rickets, bowed or curved legs, short stature, bone and joint pain, muscle weakness, dental abscesses, and hearing problems, though presentation differs by age and severity. Diagnosis usually involves blood and urine phosphate testing, X-rays, and genetic confirmation, while treatment may include targeted FGF23-blocking therapy, phosphate and active vitamin D supplements, and orthopedic or dental care. There are several important factors to consider, including how symptoms overlap with other bone and mineral conditions, so review the complete details below before drawing conclusions.

Because XLH symptoms are easy to mistake for growing pains, nutritional rickets, or ordinary joint problems, a fast and structured review of what you are experiencing can help you decide how urgently to seek care, and a free, instant, online symptom check can help you organize your symptoms and understand your next steps.

Last reviewed for medical accuracy: 08/18/2026

answer background

Explanation

What Is X-Linked Hypophosphatemia?

X-linked hypophosphatemia (XLH) is a rare genetic disorder that affects the way your body handles phosphate, a mineral critical for healthy bones and teeth. In XLH, low levels of phosphate in the blood lead to soft, weak bones—a condition often called rickets in children and osteomalacia in adults.

How XLH Develops

XLH is caused by a mutation in the PHEX gene, located on the X chromosome. This mutation disrupts normal phosphate regulation:

  • In healthy individuals, PHEX helps control levels of a hormone called fibroblast growth factor 23 (FGF23).
  • In XLH, mutated PHEX allows FGF23 levels to rise.
  • High FGF23 causes the kidneys to waste phosphate, leading to chronically low blood phosphate.

Because the gene is on the X chromosome:

  • Males (XY) who inherit the mutation from their mother will develop XLH.
  • Females (XX) who inherit one altered copy may have milder or variable symptoms, depending on X-chromosome inactivation.

Who Gets XLH?

  • XLH affects about 1 in 20,000 to 1 in 60,000 people worldwide.
  • It appears in every ethnic group and in both sexes, though symptoms can be more severe in males.
  • A family history of unexplained rickets, bone pain or short stature may raise suspicion.

Key Symptoms and Signs

XLH often becomes apparent in early childhood but may go undiagnosed until adulthood. Look out for:

  • Bone abnormalities
    – Bowed legs or knock-knees
    – Short stature compared with peers
    – Wide wrists and ankles
  • Bone pain and stiffness
  • Muscle weakness
  • Dental issues
    – Recurrent cavities
    – Abscesses without obvious decay
  • Delayed walking and developmental milestones in children
  • Pseudofractures (Looser zones) seen on X-rays

Symptoms can vary in intensity. Some adults may notice joint stiffness, early osteoarthritis or fatigue rather than obvious bone deformities.

How XLH Is Diagnosed

A healthcare provider will look at clinical signs and use tests to confirm XLH:

  1. Blood tests
    • Low serum phosphate
    • High or inappropriately normal FGF23
    • Normal calcium and parathyroid hormone levels
  2. Urine tests
    • Increased phosphate excretion
  3. Imaging
    • X-rays showing rickets, pseudofractures or bone deformities
  4. Genetic testing
    • Identifies mutations in the PHEX gene
    • Useful for at-risk family members

Early diagnosis helps start treatment sooner, reducing complications.

Treatment Options

Managing XLH focuses on restoring phosphate balance and supporting bone health. Common therapies include:

  • Oral phosphate supplements
    – Taken multiple times a day to raise blood phosphate
  • Active vitamin D analogs (e.g., calcitriol)
    – Improve phosphate absorption from the gut
  • Burosumab (monoclonal antibody)
    – Targets excess FGF23
    – Given by injection every 2–4 weeks
  • Physical therapy
    – Strengthens muscles
    – Improves mobility
  • Orthopedic interventions
    – Bracing or surgery to correct severe bone deformities

Many people benefit from a multidisciplinary team: endocrinologists, orthopedic surgeons, dentists, and physical therapists.

Lifestyle and Home Care

In addition to medical treatments, these measures can help you manage XLH:

  • Balanced diet
    – Rich in calcium and phosphate (dairy products, fish, nuts)
    – Avoid excessive vitamin D fortified foods unless directed
  • Safe exercise
    – Low-impact activities like swimming or cycling
  • Regular dental check-ups
    – Early treatment of cavities and infections
  • Monitoring growth and symptoms
    – Keep a symptom diary
    – Report new pain, muscle weakness or gait changes promptly

Potential Complications

With proper care, many people lead active lives. However, be aware of:

  • Bone deformities that may need surgical correction
  • Joint pain or early osteoarthritis
  • Dental abscesses even with good oral hygiene
  • Kidney stones from phosphate and vitamin D therapy
  • Hearing loss in some patients

Regular follow-up with your healthcare team helps catch and manage these issues early.

Living Well with XLH

Adjusting to life with XLH involves:

  • Building a support network—family, friends, and patient groups
  • Setting realistic goals for daily activities
  • Staying informed about new treatments and research advances
  • Working closely with your healthcare team to adjust therapies

Talking with others who have XLH can offer practical tips and emotional support.

When to Seek Medical Advice

Monitor for any new or worsening symptoms. If you experience:

  • Sudden, severe bone or joint pain
  • Signs of kidney stones (pain in the side/back, blood in urine)
  • Persistent dental infections
  • Difficulty walking or rapid changes in gait

…seek medical attention promptly. If you’re ever unsure whether your symptoms are serious, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker.

Outlook and Research

XLH was once thought untreatable, but research has brought promising advances:

  • Burosumab has shown improvements in phosphate levels, bone healing and quality of life.
  • Ongoing studies are exploring new ways to target FGF23 and improve bone metabolism.

Early detection and modern treatments mean many people with XLH can enjoy better growth, less pain and stronger bones than ever before.


Note: This information is intended for educational purposes and should not replace professional medical advice. Always speak to a doctor about any condition that could be life threatening or serious.

(References)

  • * Haffner D, Emma F, Eastwood DM, Biosse Duplan M, Bacchetta J, Schnabel D, Wicart P, Bockenhauer D, Santos F, Levtchenko E, Harvengt P, Kirchhoff M, Di Rocco F, Chaussain C, Brandi ML, Savendahl L, Briot K, Kamenicky P, Rejnmark L, Linglart A. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol. 2019 Jul;15(7):435-455. doi: 10.1038/s41581-019-0152-5. PMID: 31068690; PMCID: PMC7136170.

  • * Linglart A, Briot K. X-linked hypophosphatemia, a genetic and treatable cause of rickets! Arch Pediatr. 2021 Oct;28(7):587. doi: 10.1016/j.arcped.2021.08.008. Epub 2021 Sep 26. PMID: 34583870.

  • * Rush ET, Johnson B, Aradhya S, Beltran D, Bristow SL, Eisenbeis S, Guerra NE, Krolczyk S, Miller N, Morales A, Ramesan P, Sarafrazi S, Truty R, Dahir K. Molecular Diagnoses of X-Linked and Other Genetic Hypophosphatemias: Results From a Sponsored Genetic Testing Program. J Bone Miner Res. 2022 Feb;37(2):202-214. doi: 10.1002/jbmr.4454. Epub 2021 Nov 10. PMID: 34633109; PMCID: PMC9298723.

  • * Ackah SA, Imel EA. Approach to Hypophosphatemic Rickets. J Clin Endocrinol Metab. 2022 Dec 17;108(1):209-220. doi: 10.1210/clinem/dgac488. PMID: 35981346; PMCID: PMC9759174.

  • * Ito N, Hidaka N, Kato H. The pathophysiology of hypophosphatemia. Best Pract Res Clin Endocrinol Metab. 2024 Mar;38(2):101851. doi: 10.1016/j.beem.2023.101851. Epub 2023 Nov 30. PMID: 38087658.

  • * Haffner D, Emma F, Seefried L, Högler W, Javaid KM, Bockenhauer D, Bacchetta J, Eastwood D, Biosse Duplan M, Schnabel D, Wicart P, Ariceta G, Levtchenko E, Harvengt P, Kirchhoff M, Gardiner O, Di Rocco F, Chaussain C, Brandi ML, Savendahl L, Briot K, Kamenický P, Rejnmark L, Linglart A. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol. 2025 May;21(5):330-354. doi: 10.1038/s41581-024-00926-x. Epub 2025 Jan 15. PMID: 39814982.

  • * Ali DS, Carpenter TO, Imel EA, Ward LM, Appelman-Dijkstra NM, Chaussain C, Jan de Beur SM, Florenzano P, Abu Alrob H, Aldabagh R, Alexander RT, Alsarraf F, Beck-Nielsen SS, Biosse-Duplan M, Crowley RK, Dandurand K, Filler G, Friedlander L, Fukumoto S, Gagnon C, Goodyer P, Grasemann C, Grimbly C, Hussein S, Javaid MK, Khan S, Khan A, Lehman A, Lems WF, Lewiecki EM, McDonnell C, Mirza RD, Morgante E, Morrison A, Portale AA, Rao C, Rhee Y, Rush ET, Siggelkow H, Tetradis S, Tosi L, Guyatt G, Brandi ML, Khan AA. X-Linked Hypophosphatemia Management in Children: An International Working Group Clinical Practice Guideline. J Clin Endocrinol Metab. 2025 Jun 17;110(7):2055-2070. doi: 10.1210/clinem/dgaf093. PMID: 39960858; PMCID: PMC12187519.

  • * Khan AA, Ali DS, Appelman-Dijkstra NM, Carpenter TO, Chaussain C, Imel EA, Jan de Beur SM, Florenzano P, Abu Alrob H, Aldabagh R, Alexander RT, Alsarraf F, Beck-Nielsen SS, Biosse-Duplan M, Cohen-Solal M, Crowley RK, Dandurand K, Filler G, Friedlander L, Fukumoto S, Gagnon C, Goodyer P, Grasemann C, Grimbly C, Hussein S, Javaid MK, Khan S, Khan A, Lehman A, Lems WF, Lewiecki EM, McDonnell C, Mirza RD, Morgante E, Morrison A, Portale AA, Rhee Y, Rush ET, Siggelkow H, Tetradis S, Tosi L, Ward LM, Guyatt G, Brandi ML. X-Linked Hypophosphatemia Management in Adults: An International Working Group Clinical Practice Guideline. J Clin Endocrinol Metab. 2025 Jul 15;110(8):2353-2370. doi: 10.1210/clinem/dgaf170. PMID: 40243526; PMCID: PMC12261105.

  • * Böckmann I, Haffner D. The Diagnosis and Therapy of XLH. Calcif Tissue Int. 2025 Apr 28;116(1):66. doi: 10.1007/s00223-025-01374-w. Epub 2025 Apr 28. PMID: 40295317; PMCID: PMC12037658.

  • * Baroncelli GI, Barale M, Brandi ML, Camozzi V, Carrara S, Nicoletti MC, Castellano E, Cetani F, Comberiati P, Iorgi ND, Eller-Vainicher C, Emma F, Fintini D, Giannini S, Gianotti L, Grandone A, Grassi G, Mora S, Palermo A, Pigliaru F, Pitea M, Procopio M, Rochira V, Ruggeri RM, Ruggiero B, Stagi S, Vezzoli G, Corbetta S. Experts' consensus on the management and treatment of individuals with X-linked hypophosphatemia across lifespan. J Endocrinol Invest. 2025 Oct;48(10):2199-2228. doi: 10.1007/s40618-025-02611-7. Epub 2025 Jul 1. PMID: 40591205; PMCID: PMC12518444.

Thinking about asking ChatGPT?Ask me instead

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.